Stock Analysis on Net

Biogen Inc. (NASDAQ:BIIB)

$22.49

This company has been moved to the archive! The financial data has not been updated since October 25, 2022.

Return on Assets (ROA)
since 2005

Microsoft Excel

Paying user area


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Calculation

Biogen Inc., ROA, long-term trends, calculation

Microsoft Excel

Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).

1 US$ in thousands


The financial data reveals several significant trends over the analyzed period. Net income attributable to the company experienced substantial growth from 2005 through 2019, rising from approximately $161 million to nearly $5.89 billion. This reflects a dynamic expansion in profitability, with some years showing particularly strong increases, such as between 2013 and 2014 and again between 2017 and 2019. However, after reaching the peak in 2019, net income shows a notable decline in the subsequent years, dropping to approximately $1.56 billion by the end of 2021.

Total assets displayed a steady overall increase from about $8.37 billion in 2005 to around $27.23 billion in 2019. This upward trend in assets indicates a consistent accumulation of resources and possibly investments in growth. Following 2019, total assets decreased somewhat, falling to approximately $23.88 billion by 2021, which may suggest divestitures, asset write-downs, or other structural adjustments within the company’s asset base.

The return on assets (ROA) exhibits a pattern correlating with net income movements. Starting at 1.92% in 2005, ROA improved sharply to peak at 21.62% in 2019, indicative of enhanced efficiency in generating profits from the asset base. Following the 2019 peak, ROA declined significantly, reaching 6.52% in 2021. This drop aligns with the observed reductions in net income and assets during the same period, pointing to decreased profitability and efficiency in asset utilization.

Profitability Trends
Net income growth was robust over the first 15 years, with notable peaks and some volatility in the later years, especially post-2019.
Asset Base Evolution
Total assets grew substantially until 2019, signaling expansion, but then contracted slightly, implying strategic or market-driven adjustments.
Efficiency and Profitability (ROA)
The ROA trend mirrors net income and asset size changes, showing high efficiency before declining sharply after 2019, highlighting challenges in maintaining profitability on assets held.

Overall, the data outlines a period of strong financial growth and increasing profitability, followed by a noticeable downturn in the latest years covered. This suggests a transition phase, with potential implications for future strategy and operations focused on restoring profitability and asset productivity.


Comparison to Competitors

Biogen Inc., ROA, long-term trends, comparison to competitors

Microsoft Excel

Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).


Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)

Biogen Inc., ROA, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)

Microsoft Excel

Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).


Comparison to Industry (Health Care)